FibroGen Inc. (NASDAQ:FGEN) traded down 2.5% during mid-day trading on Monday . The company traded as low as $19.22 and last traded at $19.40, with a volume of 141,448 shares changing hands. The stock had previously closed at $19.90.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Credit Suisse Group AG restated a “buy” rating on shares of FibroGen in a report on Wednesday, May 25th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $33.50.

The firm’s market capitalization is $1.22 billion. The stock has a 50 day moving average of $17.48 and a 200-day moving average of $18.36.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.11. Analysts predict that FibroGen Inc. will post ($1.02) EPS for the current year.

In other FibroGen news, insider K Peony Yu sold 2,344 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $17.96, for a total transaction of $42,098.24. Following the completion of the sale, the insider now directly owns 210,257 shares of the company’s stock, valued at $3,776,215.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Pat Cotroneo sold 1,796 shares of the company’s stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $16.49, for a total transaction of $29,616.04. Following the sale, the chief financial officer now directly owns 138,114 shares of the company’s stock, valued at $2,277,499.86. The disclosure for this sale can be found here.

Other hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares in the last quarter. Nationwide Fund Advisors raised its stake in FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 393 shares in the last quarter. Swiss National Bank raised its stake in FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares in the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new stake in FibroGen during the fourth quarter worth approximately $3,067,000. Finally, California Public Employees Retirement System purchased a new stake in FibroGen during the fourth quarter worth approximately $3,397,000.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.